Evozyne
AI-driven biotech company engineering novel proteins for therapeutics and sustainability.
About
Technology stack
detected 2026-06-17No comments yet. Be the first to share your take.
What does Evozyne do?
Evozyne designs novel therapeutic proteins using generative AI to address challenges in immune-mediated diseases. Their AI-native platform, EvoGen, creates new protein mechanisms optimized for potency, stability, and specificity, which are then built and tested in their EvoLab facility. Evozyne translates these engineered proteins into their pipeline for immune therapies, serving patients with high unmet needs where current treatments fail.
How much funding has Evozyne raised?
Evozyne has raised a total of $135M in funding. The most recent round on record is Series B.
Where is Evozyne headquartered?
Evozyne is headquartered in Chicago, United States.
When was Evozyne founded?
Evozyne was founded in 2020.
What industry does Evozyne operate in?
Evozyne operates in Biotechnology, AI, Drug Discovery, Generative AI, Protein Engineering.
How many employees does Evozyne have?
Evozyne has approximately 54 people on record.